Trial | NCT04296786  Report issue

Title

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
Sintilimab Combined With Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Single Arm Phase II Study

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Recruiting

  • Study Participants

    52
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.
This is a single-arm phase 2 study with fixed does of combined Sintilimab and Chidamide regimen. This regimen is repeated every 21 days. Sintilimab (200mg) is administered intravenously on day 1 of every cycle. Chidamide is used 20mg twice per week continuously. From the beginning of the trial, sindilimab will be used for 96 weeks, until disease progress, intolerable toxicity or patient/investigator discretion. Patients will continue to receive Chidamide treatment until disease progression, unacceptable toxicity, or patient/investigator discretion.

The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment. The patients who achieve complete remission (CR), partial remission (PR), and stable disease (SD) will receive further treatment. The patients with progressed disease (PD) will be continue on the treatment and reassess after 4-8 weeks to rule out false progression. On confirmation of PD , patients will be withdrawn from the trial and receive salvage regimens.
Study Started
Nov 01
2019
Primary Completion
Dec 31
2022
Anticipated
Study Completion
Dec 31
2024
Anticipated
Last Update
Mar 05
2020

Drug Sintilimab

200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment

Drug Chidamide

20mg po per week continuously

Chidamide plus Sintilimab Experimental

Patients in experimental group will receive fixed does of Sintilimab and Chidamide. This regimen is repeated every 21 days. The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment.

Criteria 

Inclusion Criteria:

Pathologically confirmed cutaneous T-cell lymphoma according World Health Organization (WHO) classification.
ECOG≤2
Patients with measurable lesions, with or without extra-dermal lesions, clinical stage of IIB-IVB.
Patients received at least one systemic treatment previously and achieved no remission or relapsed after first-line treatment.
Absolute neutrophil count (ANC）≥0.75×109/L，platelet (PLT) ≥ 50×109/L，hemoglobin (HGB）≥ 80 g/L
Thyroid stimulating hormone (TSH) within normal range

Exclusion Criteria:

Pre-existing uncontrolled active infection
Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN), total bilirubin (TBIL) >1.5 times ULN, serum creatinine >1.5 times ULN
Patients with clinically significant QT interval prolongation (male > 450ms, female > 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), acute coronary syndrome (ACS) within 1 year, congestive heart failure (CHF), and symptomatic coronary heart disease.
Patients who have received organ transplantation or hematopoietic stem cell transplantation.
Active bleeding or recent thrombotic disease
Patients with known interstitial lung disease
Patients with active autoimmune disease or history of autoimmune disease in the past 2 years
Patients with CNS involvement
Pregnant or lactating women
History of mental illness
No Results Posted